瑞康医药股东招商慧泽减持计划实施完毕 持股比例降至5%以下

Core Viewpoint - The major shareholder of Ruikang Pharmaceutical has completed a share reduction plan, which does not affect the company's control or governance structure [1]. Summary by Sections Shareholder Actions - The shareholder, Jiangzhou Zhaoshang Huize Pharmaceutical Investment Partnership, reduced its holdings by 100 shares at an average price of 3.00 yuan, representing a decrease of 0.0001% [1]. - After the reduction, the total shares held by Jiangzhou Zhaoshang Huize decreased from 75,235,525 shares to 75,235,425 shares, with the holding percentage dropping from 5.00% to 4.9999% [1]. Compliance and Impact - The company stated that the share reduction complies with relevant laws and regulations and was executed according to a previously disclosed plan, indicating no violations [1]. - Jiangzhou Zhaoshang Huize is not the controlling shareholder or actual controller of the company, and the reduction will not lead to any change in control or impact the company's governance structure and ongoing operations [1].